- Last Close 21.31
- Sector Healthcare
- Industry Drug Manufacturers - Specialty & Generic
- Investment Style Small Blend
- Day Range 21.18 – 21.75
- Year Range 17.45 – 35.40
- Market Cap 3.7864 Bil
- Volume / Avg 121,700.0 / 426,321.0
- Price / Sales 2.85
- Price / Book 2.08
- Forward Div Yield 3.40%
- Trailing Div Yield 3.88%
Morningstar‘s Stock Analysis BLAU3
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile BLAU3
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
Cotia, SP, 06705-030, BRA
Competitors & Peers
Morningstar does not cover competitors or peers for this firm.
FAQs for Blau Farmaceutica SA Stock
Yes. BLAU3 has a forward dividend yield of 3.40%.
BLAU3’s full dividends and stock split history
on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
BLAU3’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
BLAU3’s price/sales is 2.85.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.
BLAU3’s price/forward earnings is 10.88.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.
BLAU3’s price/book is 2.08.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See BLAU3’s valuation ratios compared to the Market Index.
BLAU3’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare BLAU3’s historical performance against its industry peers and the overall market.